Core Viewpoint - The company intends to utilize part of its idle raised funds and self-owned funds for cash management, ensuring that this does not affect the construction of investment projects or the normal operation of the company [1][6][8]. Fundraising Basic Situation - The company has been approved to publicly issue 40.01 million shares at a price of RMB 23.60 per share, raising a total of RMB 944.236 million, with issuance costs amounting to RMB 65.914 million [1][2]. Fund Management and Usage - The raised funds are stored in a special account, and a tripartite supervision agreement has been signed with the bank and the sponsor to ensure proper management [2][3]. - The net amount from the fundraising will be used for main business-related projects, including a production project for low-melting point polyester fibers and a recycling short fiber R&D center [2][3]. Cash Management Details - The company plans to use up to RMB 260 million of idle raised funds and up to RMB 1.4 billion of idle self-owned funds to purchase safe, liquid, principal-protected financial products, with individual product terms not exceeding 12 months [3][5]. - The cash management will be valid for 12 months from the board's approval, allowing for rolling use of funds within the specified limits [3][5]. Investment Products and Implementation - The cash management products will be of high safety and liquidity, and will not be used for pledging or securities investment purposes [5][6]. - The board has authorized the management to make investment decisions within the approved limits, with the finance department responsible for implementation [5][6]. Risk Management and Control - The company will select financial institutions with strong capital security capabilities and will maintain close contact to monitor the operation of the invested funds [6][7]. - The company will ensure that the cash management does not affect the implementation of investment projects or the normal operations of the company [6][7]. Approval Process - The board and supervisory committee have approved the cash management proposal, which does not require shareholder approval [7][8]. - The supervisory committee believes that this cash management will enhance the efficiency of fund usage without altering the intended use of the raised funds [7][8]. Sponsor's Opinion - The sponsor has confirmed that the cash management plan complies with relevant laws and regulations, and does not constitute a change in the use of raised funds [8].

Core Viewpoint - The company plans to utilize idle self-owned funds amounting to RMB 1.7 billion for cash management, aiming to enhance the efficiency of fund usage while ensuring normal business operations are not affected [1][2]. Investment Overview - **Investment Purpose**: The objective is to improve the efficiency of self-owned funds and achieve capital preservation and appreciation for the company and its shareholders [2]. - **Investment Amount**: The company intends to use up to RMB 1.7 billion of idle self-owned funds for cash management, which can be rolled over within this limit [2]. - **Source of Funds**: The funds will come from temporarily idle self-owned resources and will not impact the company's normal operations [2]. - **Investment Method**: The company will purchase high-safety, high-liquidity financial products, including but not limited to notice deposits, structured deposits, and large certificates of deposit, ensuring these products are not used for pledging or securities investment [2]. - **Investment Period**: The funds can be used in a rolling manner for 12 months from the previous cash management authorization, specifically from September 2, 2025, to September 1, 2026 [2]. Review Procedures - The company held the tenth meeting of the second board and the tenth meeting of the second supervisory board on August 27, 2025, where the proposal for cash management was approved, and the supervisory board expressed clear agreement [2][4]. Impact on the Company - Utilizing idle self-owned funds for cash management will not affect the normal development of the company's main business. This approach is expected to enhance the efficiency of fund usage, benefiting the company and all shareholders [4][5]. - According to the new financial instrument standards issued by the Ministry of Finance, the principal of this cash management will be recorded as trading financial assets on the balance sheet, while interest income will be recorded as investment income on the profit statement, subject to annual audit results [4]. Supervisory Board Opinion - The supervisory board agrees that using up to RMB 1.7 billion of idle self-owned funds for purchasing high-safety, high-liquidity financial products is appropriate, ensuring no impact on normal operations and fund safety, and that necessary review procedures have been followed [4][5].

Meeting Overview - The second board meeting of Beijing Innotech Biotechnology Co., Ltd. was held on August 27, 2025, with all 9 directors present, and the meeting complied with relevant laws and regulations [1]. Financial Reports - The board approved the 2025 semi-annual report and its summary with a unanimous vote of 9 in favor [2]. - The board also approved a special report on the storage and actual use of raised funds for the first half of 2025, confirming compliance with regulations and proper use of funds [2]. Cash Management - The board agreed to use up to RMB 300 million of idle raised funds for cash management, allowing for the purchase of safe and liquid financial products, with a rolling usage period from September 2, 2025, to September 1, 2026 [3]. - Additionally, the board approved the use of up to RMB 1.7 billion of idle self-owned funds for similar cash management purposes during the same period [4]. Stock Incentive Plan - The board approved an adjustment to the grant price of the 2023 restricted stock incentive plan from RMB 13.20 per share to RMB 12.65 per share [5]. - A semi-annual evaluation report on the "Quality Improvement and Efficiency Enhancement" action plan for 2025 was also approved [6]. Corporate Governance Changes - The board approved changes to the registered capital and the cancellation of the supervisory board, allowing the audit committee to assume its responsibilities [7]. - The board agreed to revise and add certain company regulations to enhance governance structure [8]. Fund Allocation - The board approved the use of RMB 60 million of surplus raised funds for the "In Vitro Diagnostic Product R&D Project" and extended the project's timeline by 18 months [10]. Stock Incentive Plan Draft - The board approved the draft of the 2025 restricted stock incentive plan, which aims to attract and retain talent while aligning interests among shareholders, the company, and core team members [11][13]. Authorization for Stock Incentive Plan - The board proposed to seek shareholder authorization for handling matters related to the 2025 restricted stock incentive plan [15]. Insurance for Directors - A proposal for purchasing liability insurance for directors and supervisors was submitted for shareholder approval due to the absence of a valid resolution [17]. Shareholder Meeting - The board approved a proposal to convene the first extraordinary general meeting of shareholders in 2025 [14].

Meeting Overview - The 21st meeting of the 4th Supervisory Board of Suzhou Ruikeda Connection System Co., Ltd. was held on August 28, 2025, with all three supervisors present [1][2]. Financial Report Approval - The Supervisory Board approved the 2025 semi-annual report, confirming that the report's preparation and review procedures comply with legal regulations and internal management systems, accurately reflecting the company's financial status and operational results [2][3]. Fund Management Report Approval - The Supervisory Board approved the special report on the management and actual use of raised funds for the first half of 2025, stating that the management of these funds complies with relevant regulations and that the disclosed information is accurate and complete [2][3]. Idle Fund Management Approval - The Supervisory Board approved the use of up to RMB 200 million of idle self-owned funds for cash management in safe and liquid investment products, ensuring that this will not affect the company's normal operations or the interests of shareholders, particularly minority shareholders [3].

Meeting Overview - The first session of the Supervisory Board's 24th meeting was held on August 27, 2025, with all five supervisors present, ensuring compliance with legal and regulatory requirements [1]. Financial Reporting - The Supervisory Board approved the 2025 semi-annual report, confirming that it accurately reflects the company's operational results and financial status, adhering to relevant regulations [2]. - The voting results for the semi-annual report were unanimous, with 5 votes in favor [2]. Fund Management - The Board approved the special report on the use of raised funds, affirming that the funds were stored and used in accordance with legal regulations, with no violations or harm to shareholder interests [2]. - The voting results for the fund management report were also unanimous, with 5 votes in favor [2]. Risk Assessment - The Board approved the continuous risk assessment report for the financial company, indicating that it has a valid financial license and a robust internal control and risk management system [3]. - The voting results for the risk assessment report were unanimous, with 5 votes in favor [3]. Asset Impairment - The Board approved the proposal for asset impairment provisions for the first half of 2025, stating that the provisions were made in accordance with accounting standards and reflect the financial situation accurately [4]. - The voting results for the asset impairment proposal were unanimous, with 5 votes in favor [4]. Cash Management - The Board approved the use of temporarily idle raised funds for cash management, ensuring that this does not affect project construction or shareholder interests [5]. - The voting results for the cash management proposal were unanimous, with 5 votes in favor [5].

Core Points - The company held its third supervisory board meeting on August 28, 2025, where all three supervisors attended, confirming the legality and validity of the meeting [1] - The supervisory board approved the 2025 semi-annual report and summary, affirming compliance with legal and regulatory requirements, and ensuring the accuracy and completeness of the disclosed information [1][2] - The board also approved the reappointment of Tianjian Accounting Firm for the 2025 financial audit, with an audit fee of 560,000 RMB, ensuring continuity and professional capability [2][6] - A proposal to abolish the supervisory board was approved, transferring its responsibilities to the audit committee of the board, in accordance with new regulations [6][7] - The board approved a profit distribution plan for the first half of 2025, emphasizing the company's commitment to reasonable returns for investors [7][8] - The company plans to utilize idle funds for cash management, investing in liquid and safe financial products to enhance fund efficiency and increase investment returns [8][10]

Core Viewpoint - The company intends to utilize temporarily idle raised funds and its own funds for cash management to enhance fund efficiency and returns while ensuring the safety of the raised funds and the normal operation of investment projects [1][4][6] Summary by Sections 1. Basic Situation of Raised Funds - The company was approved to publicly issue 25,666,700 shares at a price of RMB 80.88 per share, resulting in a net raised amount of RMB 606,213,138.68 after deducting issuance costs [1][2] 2. Investment Project Situation - The raised funds will be invested in two main projects: the development and industrialization of a laser flexible precision manufacturing control platform and the establishment of marketing and technical support networks, with a total investment of RMB 39,591.79 million [2] 3. Cash Management Basic Situation - The purpose of using idle raised funds and self-owned funds for cash management is to improve efficiency and returns without affecting the construction of investment projects or the safety of raised funds [3][4] 4. Investment Products - The company plans to invest in low-risk, high-security, and liquid financial products, including structured deposits, time deposits, and money market funds, ensuring that these funds are not used for pledging or securities investment [3][4] 5. Investment Limits and Duration - The total amount for cash management will not exceed RMB 40,000.00 million for both idle raised funds and self-owned funds, with a validity period of 12 months from the board's approval [4][5] 6. Information Disclosure - The company will comply with relevant regulations for timely information disclosure regarding cash management activities [4] 7. Implementation Method - The board has authorized the management to make decisions within the specified limits, including selecting qualified financial product issuers and signing contracts [4][5] 8. Impact on the Company - The cash management of idle funds is expected to enhance fund efficiency and returns without affecting the company's daily operations or investment projects [4][6] 9. Review by the Sponsor Institution - The sponsor institution has confirmed that the cash management plan complies with relevant regulations and will not alter the intended use of raised funds, thus protecting the interests of the company and its shareholders [6]

证券代码：603566 证券简称：普莱柯 公告编号：2025-034 普莱柯生物工程股份有限公司 二、董事会会议审议情况 具体内容详见上海证券交易所网站（www.sse.com.cn）相关公告。 本议案已经公司第五届董事会审计委员会第十四次会议审议通过，同意提交 董事会审议。 表决结果：9 票赞成，0 票反对，0 票弃权。 为提高公司暂时闲置募集资金使用效率，在确保募集资金投资项目建设正常 开展、募集资金安全的前提下，公司拟对额度不超过人民币 2.1 亿元的暂时闲置 募集资金进行现金管理，投资产品为安全性高、流动性好的保本型理财产品。本 议案已经公司第五届董事会审计委员会第十四次会议审议通过，同意提交董事会 审议。 具体内容详见上海证券交易所网站（www.sse.com.cn）相关公告。 表决结果：9 票赞成，0 票反对，0 票弃权。 关于第五届董事会第十九次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 普莱柯生物工程股份有限公司（以下简称"公司"）第五届董事会第十九次 会议于 2025 ...

Meeting Overview - The fifth meeting of the Supervisory Board of the company was held on August 28, 2025, with all three supervisors present, confirming the legality and validity of the meeting [1]. Financial Reporting - The 2025 semi-annual report was approved, confirming that its content and format comply with the regulations of the China Securities Regulatory Commission and the stock exchange, accurately reflecting the company's operational results and financial status [1][2]. - The report disclosed no false records, misleading statements, or significant omissions, and no violations of confidentiality by the personnel involved in its preparation were found [1]. Fund Management - The company confirmed that the use of raised funds complies with relevant regulations, with no changes in the purpose of the funds or harm to shareholder interests [2]. - The profit distribution plan for 2025 was deemed compliant and reasonable, ensuring the company's sustainable development while sharing profits with shareholders [2]. - The Supervisory Board approved the temporary use of up to 210 million yuan of idle raised funds for cash management, ensuring it would not affect normal business operations [3]. - Additionally, the company approved the use of 250 million yuan of idle self-owned funds for cash management under necessary approval procedures [3]. Related Transactions - The wholly-owned subsidiary, Luoyang Lepet Health Technology Co., Ltd., plans to acquire four "Meng Tuan" trademarks from Century Mengbang (Shanghai) Information Technology Co., Ltd. for 10,000 yuan, which aligns with the company's pet business development strategy and enhances brand competitiveness [4].

Core Viewpoint - The company has approved an increase in the use of its own funds for cash management, raising the total limit to 1.95 billion RMB, aimed at improving fund efficiency and returns while ensuring daily operational needs are met [1][2][4]. Investment Overview - **Investment Purpose**: The company aims to enhance fund utilization efficiency, reduce financial costs, and increase returns for the company and its shareholders while ensuring the safety of daily operational funds [2]. - **Investment Amount**: The board approved an initial amount of up to 1.4 billion RMB for cash management, which was later increased by an additional 550 million RMB, bringing the total to 1.95 billion RMB [2][4]. - **Source of Funds**: The funds for cash management will come from short-term idle self-owned funds [2]. - **Investment Method**: The chairman is authorized to manage the use of self-owned funds for cash management, with the finance department responsible for implementation [2]. Investment Duration - The investment decision is valid until the next board meeting that reviews the cash management proposal, with a maximum usage period of 12 months, allowing for rolling use within the approved limits [3]. Review Procedures - The company held board and supervisory meetings on April 21, 2025, to approve the initial cash management proposal and subsequently on August 28, 2025, to approve the increase in the cash management limit [3][4]. Impact on the Company - Utilizing self-owned funds for cash management will not affect the company's normal cash flow or the development of its main business, and is expected to improve fund efficiency and returns for the company and its shareholders [5].